Solubility of Flurbiprofen in Supercritical Carbon Dioxide by Duarte, Ana Rita C. et al.
Solubility of Flurbiprofen in Supercritical Carbon Dioxide
Ana Rita C. Duarte,† Patrı´cia Coimbra,‡ Hermı´nio C. de Sousa,‡ and Catarina M. M. Duarte*,†
Instituto de Biologia Experimental e Tecnolo´gica, Aptd. 12-2780 Oeiras, Portugal, and Dep. de Engenharia
Quı´mica, FCT, Universidade de Coimbra, Po´lo IIsPinhal de Marrocos, 3030-290 Coimbra, Portugal
Equilibrium solubility of flurbiprofen, a nonsteroidal antiinflammatory agent, in supercritical carbon
dioxide was measured by a static analytical method in the pressure range from (8.0 to 25.0) MPa, at
temperatures of (303.0, 313.0, and 323.0) K. The cosolvent effect of ethanol in the solubility of the bioactive
compound in supercritical carbon dioxide was investigated at 18 MPa and 313 K. The results obtained
have a potential application in supercritical processes for this drug. Experimental solubility data were
correlated with an empirical density-based Chrastil model.
Introduction
This work is part of a research project designed for the
development of polymeric controlled drug release systems
(CDRS) for ophthalmic applications, namely, for glaucoma
and several other corneal pathologies treatment, using
“clean and environmental friendly” supercritical processes.
In products for medical and pharmaceutical applications,
the presence of residual organic solvents is rigorously
controlled by international safety regulations. Thus, it is
necessary to warrant the complete removal and absence
of these substances, without exposing the polymers and
drugs contained in a typical polymeric CDRS to high
temperatures that could degrade them. In this sense,
supercritical fluids (SCFs) can be very attractive solvents.
Supercritical carbon dioxide (Tc ) 31 °C and Pc ) 73 bar),
due to its relatively low critical temperature, is less likely
to degrade thermally labile substances. SC carbon dioxide
has other important advantages, including the fact that it
is nontoxic, nonflammable, and inexpensive. Some CDRSs
and other medical applications have been developed using
techniques involving SC CO2.1-8 The design of chemical and
pharmaceutical processes based on SCFs and the deter-
mination of their best operating conditions requires a
knowledge of phase equilibria and drug solubility in a
supercritical fluid. In the last two decades, solubility in
SCFs of a large number of different low-volatility com-
pounds have been measured, reported, and reviewed.9-16
However, the development of new supercritical processes
and new applications for existing substances has main-
tained the need for new experimental solubility determina-
tions.
For organic compounds having high molecular masses,
supercritical solubility is usually low. Thus high temper-
atures and pressures are required for substantial solid
loadings in a supercritical phase. For example, although
carbon dioxide is the most common SCF used by industry,
it does have limitations due to its lack of polarity and its
associated deficiency of specific solvent-solute interactions
which would lead to high loading and/or selectivity for polar
organic compounds. To improve polarity/selectivity, it was
found that the addition of small amounts of a so-called
cosolvent or entrainer (usually a polar substance) to a SCF
can produce dramatic effects on its solvent power, some-
times up to several hundred percent of solubility enhance-
ment.17,18 The entrainer can be a gas, a liquid, or a
supercritical fluid.19
Flurbiprofen (Figure 1) is a well-known chiral nonster-
oidal antiinflammatory agent with analgesic and anti-
pyretic activity. It is one of the most potent inhibitors of
platelet aggregation, and it is used to treat gout, osteoar-
thritis, rheumatoid arthritis, and sunburn. In ophthalmic
applications, it is used to prevent pupil constriction and to
reduce pain and inflammation in the eye. Because it does
not influence intraocular pressure, it can be prescribed to
patients suffering from glaucoma.20,21
In this work, the equilibrium solubility of flurbiprofen
in supercritical carbon dioxide was measured from (8.0 to
25.0) MPa at (303.0, 313.0, and 323.0) K. The effect of
adding ethanol as a cosolvent in the solubility of the
bioactive compound in supercritical carbon dioxide was
investigated at 18.0 MPa and 313.0 K. The static analytical
apparatus used for solubility measurements is briefly
described and the experimental procedure presented. Solu-
bility data results were correlated applying the Chrastil’s
empirical density-based model.
Experimental Section
Materials. Flurbiprofen, CAS [5104-49-4] (97% purity)
was purchased from Sigma-Aldrich. Dichloromethane, CAS
[75-09-2] (99.95% purity), was purchased from Fluka.
Ethanol, CAS [64-17-5] (99.8% purity), was purchased from
Riedel-de Ha¨en. Carbon dioxide (99.998 mol %) was sup-
plied by Air Liquide. All chemicals were used without any
further purification.
* To whom correspondence should be addressed. E-mail: cduarte@
itqb.unl.pt. Fax: +351 21 4421161.
† Instituto de Biologia Experimental e Tecnolo´gica.
‡ Universidade de Coimbra.
Figure 1. Chemical structure of flurbiprofen, CAS [5104-49-4],
2-fluoro-alpha-methyl-4-biphenylacetic acid.
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Experimental Procedures. The solubility of flurbipro-
fen was measured using a static analytic high-pressure
apparatus, schematically presented in Figure 2. The de-
termination of the solubility was performed in a similar
manner to that described by Matias et al.22 A stainless steel
equilibrium visual cell, with an internal volume of ap-
proximately 30 cm3, is immersed in a thermostatic water
bath, heated by means of a controller that maintained
temperature within (0.1 °C. The cell is initially loaded
with the solid and a magnetic internal stirrer. Carbon
dioxide is pumped into the cell using a pneumatic compres-
sor until the desired pressure is attained. The pressure
inside the cell is measured with a pressure transducer
(SETRA, model 204, (0 to 34.40 ( 0.04) MPa), calibrated
between 0 and 20.6 MPa.
The mixture of CO2 + flurbiprofen is stirred for 1 h, a
typical equilibration time. After 30 min of rest for equili-
bration, samples from the gas (top) phase are taken
through a six-port sampling HPLC valve. These samples
are collected by a quick depressurization and expansion
into a small glass trap. The gas in the samples is expanded
into calibrated volumes, and the amount of CO2 in each
sample is calculated from the measurement of the resulting
subatmospheric pressure increase at the working temper-
ature.
Pressure, after the expansion, is measured with a
pressure transducer (SETRA, model 204, (0 to 0.17 ( 1.9
 10-4) MPa). To ensure that all solute is recovered in the
trap, ethanol is injected through the sample loops and
expansion lines. Finally, the lines are cleaned with fresh
carbon dioxide smoothly pressurized.
For the experiments with cosolvent, to ensure that the
molar fraction of ethanol was kept constant, some changes
were made in the experimental apparatus. A manual
syringe pump (HIP, model 87-6-5) was coupled to the
system and was kept under constant temperature with
circulating water coming from a thermostatic bath. In all
these experiments, the cell was pressurized with the
mixture of ethanol and carbon dioxide inside this syringe
pump.
Analytical Method. The collected samples were diluted
in ethanol to a convenient volume. To determine the
amount of flurbiprofen, the resulting solutions were ana-
lyzed by UV spectrophotometry in a UV-vis (Cary 3Es
Varian). Flurbiprofen absorbs in the region of ultraviolet,
with a maximum absorbance at 247 nm. Calibration was
obtained by using of standard samples with concentrations
between (1.0  10-5 and 2.0  10-4) M.
Results and Discussion
In this work, the solubility of flurbiprofen in carbon
dioxide was determined at 303.0 K, 313.0 K, and 323.0 K,
from (8.0 to 25.0) MPa. In Table 1 and Figure 3, the
solubility of flurbiprofen is expressed in terms of flurbi-
profen mole fraction (yflurbiprofen) and in terms of mass of
solute per unity of volume of supercritical CO2. Each data
point is the average of, at least, two measurements with
an average absolute relative deviation, AARD, of 9
where Sexp and Scalc are the experimental and calculated
solubilities for n data points.
At the three studied temperatures, the effect of pressure
on the solute solubility follows the expected trend. The
solvent capacity increases with pressure at constant tem-
perature. This can be easily explained in simple physical
terms. Density rises with increasing pressure, which means
that the intermolecular mean distance of the molecules
decreases and consequently the specific interaction between
the solute and the solvent molecules increases, leading to
higher solubility. Temperature is also an important but
more complex factor affecting solubility results. It also
Figure 2. High-pressure apparatus for solubility measure-
ments: 1, CO2 compressor; 2, rupture disk; 3, thermostatic water
bath; 4, six port-sampling HPLC valve; 5, manual syringe; P,
pressure transducer; TC, temperature controller; C, equilibrium
cell with sapphire windows; T, glass trap; B, expansion-calibrated
cylinder.
Figure 3. Solubility isotherms of flurbiprofen in supercritical
carbon dioxide as a function of pressure: *, 303.0 K; 0, 313.0 K;
2, 323.0 K. Lines represent a polynomial fit to the experimental
data points.
Table 1. Solubilities of Flurbiprofen in Supercritical
Carbon Dioxide
T/K P/MPa FCO2/g L-1 26 yflurbiprofen (105) solubility in CO2/g L-1
303 8.9 747.7 2.17 0.10
11.2 791.4 2.897 0.13
13.1 821.7 3.530 0.16
14.1 834.7 4.144 0.19
15.3 847.6 5.312 0.25
17.3 867.4 5.991 0.28
18.5 878.7 6.236 0.30
19.5 887.1 7.259 0.36
21.9 906.0 7.896 0.40
23.1 913.5 8.211 0.42
24.5 921.4 8.337 0.43
313 9.8 616.9 1.672 0.06
11.8 714.0 3.608 0.14
13.1 746.1 5.389 0.22
14.1 767.7 5.250 0.22
15.3 786.3 6.646 0.29
17.1 811.7 8.116 0.37
20.2 807.2 12.563 0.52
23.4 841.7 13.904 0.55
24.4 876.6 14.950 0.73
323 11.2 534.0 2.603 0.08
13.3 654.6 5.272 0.19
16.6 736.1 10.179 0.42
17.7 767.1 14.012 0.60
19.7 784.0 14.838 0.65
20.6 792.0 16.213 0.71
23.4 823.6 19.683 0.90
AARD (%) )
100
n
∑
1
n jScalc - Sexpj
Sexp
(1)
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influences solute vapor pressure, solvent density, and
intermolecular interactions in the fluid phase. Figure 3
shows that the observed solubility values were higher with
decreasing temperatures until a crossover region was
reached, near 12.0 MPa, where the three isotherms seem
to intercept and cross over each other. The decrease in SC
CO2 density with increasing temperature prevails, at lower
pressures, resulting in a decrease of the SCF solvent power
and solubility. Above this crossover region, the effect of the
temperature on solute vapor pressure overlays the effect
on solvent density and solubility increases with increasing
temperature.
Ethanol is one of the few organic solvents considered
suitable for contact with products for human consumption,
at moderate concentrations. Ethanol cosolvent’s effect in
flurbiprofen’s solubility in SC CO2 was studied at 18.0 MPa
and 313.0 K. Four different ethanol concentrations, 2.5, 5.0,
7.5, and 10.0 mol %, were investigated. The results
obtained are indicated in Table 2 and illustrated in Figure
4, where the solubility enhancement of flurbiprofen in the
supercritical phase is plotted as a function of the ethanol
concentration. The enhancement factor of cosolvent corre-
sponds to the ratio between the solubility of flurbiprofen
in the presence of ethanol and the solubility in pure carbon
dioxide, and it follows an exponential trend.
Correlation of Experimental Solubility Data. Hav-
ing experimental solubility data in SCF solvents, it is also
useful to develop theoretical models to correlate and predict
solid-fluid equilibrium, which afterward can be used to
optimize SCF processes. Usually the SCF is treated as a
compressed gas, and pressure and/or density are chosen
as the independent variables. Thus, equations of state
(EOS) and, undoubtedly, simple cubic EOS, together with
different mixing and combining rules, are the most widely
used models to correlate and predict solid-SCF equilibri-
um.17 However, even simple and more general cubic EOS
normally require critical parameters and acentric factors
for solvent and solutes that are frequently unavailable in
the literature, especially for pharmaceutical compounds,
polymers, biomolecules, and other less common substances.
Other difficult to obtain thermophysical data include
intermolecular energy parameters, boiling points, melting
points, solid molar volumes, sublimation and vaporization
enthalpies, and vapor-pressure curves. Moreover, the avail-
able estimation methods found in the literature for such
complex molecules are mostly empirical and often lead to
inconsistent and unreliable results.16,23 Another disadvan-
tage is that most models require one or more temperature-
dependent interaction parameters which must be corre-
lated from experimental solubility data. More complicated
EOS models (e.g., SAFT) and mixing rules (e.g., Wong-
Sandler) were developed but still need more adjustable
parameters.24
To avoid some of these disadvantages as well as more
complicated computational routines, most authors opt to
use more simple empirical correlations such as density-
based equations. These empirical models are based on
simple error minimization using least-squares methods,
and for the majority of them, there is no need to estimate
and use thermophysical properties. The most commonly
used model is Chrastil’s model,25 which correlates the
solubility of a solute, in a supercritical solvent, to the
density and temperature. This model is based on the
hypothesis that each molecule of a solute associates with
k molecules of supercritical solvent, to form a solvato
complex, which is in equilibrium with the system. The
Chrastil’s relationship between solubility and density can
be expressed as
where S is the solubility (g L-1) of flurbiprofen in SC CO2,
F is the density (g L-1) of the pure CO2 at the experimental
absolute temperature (K), T, and pressure, p. The constant,
k, expresses an average equilibrium association number,
which is a characteristic constant for a given gas-solute
system. The parameter a is defined as ¢H/R, where ¢H is
the sum of the enthalpies of vaporization and solvation.
Finally, the parameter b is dependent on the molecular
weights of solvent and solute.
Correlation and prediction of the solubility of flurbiprofen
in supercritical CO2 is very important for the application
of supercritical fluid technology in processing this bioactive
compound. In this work, the experimental solubility data
for flurbiprofen were correlated using the previously
described semiempirical Chrastil method. The logarithmic
solubility-density relationship shows a linear behavior for
all the isotherms, as it is illustrated in Figure 5. By
performing a multiple linear regression on ln S as a
function of ln F and 1/T, one obtains k ) 6.5 ((0.2), a )
-7582 ((232), and b ) -20.3 ((0.8). The thermodynamic
quantity, ¢H, can be calculated directly from a, resulting,
for the studied system, in a value of -62.98 kJ mol-1. The
average absolute relative deviation of the fitted Chrastil
equation from experimental data was calculated to be 10%.
Conclusions
Equilibrium solubility of flurbiprofen in supercritical CO2
was measured by a static analytical method, in the pres-
sure range from (8.0 to 25.0) MPa at (303.0, 313.0, and
323.0) K. Equilibrium solubility data, expressed in terms
Figure 4. Enhancement factor of cosolvent at 18.0 MPa and 313.0
K as a function of ethanol molar fraction. The line represents the
exponential fit to the data points.
Table 2. Experimental Solubility of Flurbiprofen in
Supercritical Carbon Dioxide, with the Addition of
Ethanol as Cosolvent at 313 K and 18.0 MPa
%
cosolvent
yflurbiprofen
(104)
solubility in
CO2/g L-1
enhancement factor
of cosolvent
0 0.4848 0.427 1
2.5 3.7648 1.713 4
5 7.8519 3.571 8
7.5 15.5522 7.088 17
10 36.7575 16.776 39
Figure 5. Logarithmic relationship between solubility of flurbi-
profen and the density of supercritical CO2 at *, 303.0 K; 0, 313.0
K; 2, 323.0 K. Lines represent Chrastil’s regression fit.
S ) Fk exp(a/T + b) (2)
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of flurbiprofen’s mole fraction, ranges from (1 to 20)  10-5,
with an AARD of 9%. At a constant temperature, the
solvent capacity increases with increasing pressure. Near
12.0 MPa, the three isotherms intercept, which reveals the
approach of a crossover region. Below this pressure value,
solubility increases with decreasing temperature, and
above 12.0 MPa, the effect of the temperature on the solute
vapor pressure overlays the effect on the solvent density,
resulting in an increase of the solubility with the temper-
ature increase.
The ethanol cosolvent effect on flurbiprofen’s solubility
in supercritical CO2 was studied at 18.0 MPa and 313.0
K. Four different ethanol concentrations (2.5, 5.0, 7.5, and
10.0) mol % were investigated. The solubility of flurbiprofen
in supercritical CO2 + ethanol follows an exponential trend.
Application of Chrastil’s density-based model to the
experimental data leads to values of k ) 6.5 ((0.2), a )
-7582 ((232), b ) -20.3 ((0.8), and ¢H ) -62.98 kJ
mol-1. These data were correlated with a maximum AARD
of 10%.
The solubility results obtained in this work are very
promising for the development of supercritical processes
for pharmaceutical applications based on this drug.
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